TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04520685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
Study: NCT06576349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassionate And Loving Mindset towards Heart Health Risk (CALM Hearts) Intervention
Description: Self-compassion and health behaviour change intervention for women at risk for cardiovascular disease
Study: NCT05015634

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Arm
Description: Patient develops possible cardiac symptoms, takes an ECG, BP and oxygen saturation as per their training. Patient will receive a phone call by the trial cardiologist who will have access to a high-quality ECG trace, as well as blood pressure and oxygen saturations, and coupled with the clinical history, can decide on the most appropriate course of further management. With remote follow up over the phone at 3, 6 and 9 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Arm
Description: Standard routine clinical care will be carried out, with remote follow up over the phone at 3, 6 and 9 months.
Study: NCT05393037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline in each 0.5 mL sterile solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV15
Description: Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV15 - Part B
Description: Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
Study: NCT06071364

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography imaging and Hand-held dynamometer (HHD)
Description: Ultrasound imaging system will be used to evaluate the thickness, cross -sectional area and fat infiltration of lumbar extensors lumbar multifidus , erector spinae and quadratus lumborum muscles.~The hand-held dynamometer assessing isometric lumbar muscles strength

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography imaging and Hand-held dynamometer (HHD)
Description: Ultrasound imaging system will be used to evaluate the thickness, cross -sectional area and fat infiltration of lumbar extensors lumbar multifidus , erector spinae and quadratus lumborum muscles.~The hand-held dynamometer assessing isometric lumbar muscles strength
Study: NCT06441604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Buprenorphine
Description: First 10 participants will receive XR-BUP 16mg in single-blind fashion. If at least 90% of the participants who received 16mg successfully complete induction (success defined as experiencing no BPOW),10 additional participants will receive a 24mg dose in a single blind fashion.~If at least 90% who received 24mg successfully complete induction (success defined as experiencing no BPOW), 10 additional participants will receive a 32mg dose in a single blind fashion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Buprenorphine
Description: First 10 participants will receive XR-BUP 16mg in single-blind fashion. If at least 90% of the participants who received 16mg successfully complete induction (success defined as experiencing no BPOW),10 additional participants will receive a 24mg dose in a single blind fashion.~If at least 90% who received 24mg successfully complete induction (success defined as experiencing no BPOW), 10 additional participants will receive a 32mg dose in a single blind fashion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Buprenorphine
Description: First 10 participants will receive XR-BUP 16mg in single-blind fashion. If at least 90% of the participants who received 16mg successfully complete induction (success defined as experiencing no BPOW),10 additional participants will receive a 24mg dose in a single blind fashion.~If at least 90% who received 24mg successfully complete induction (success defined as experiencing no BPOW), 10 additional participants will receive a 32mg dose in a single blind fashion.
Study: NCT06535334

Intervention type: DRUG
Intervention: Chemotherapy
Description: Intravenous chemotherapy versus intraperitoneal chemotherapy in recurrent ovarian cancer

Intervention type: DRUG
Intervention: Chemotherapy
Description: Intravenous chemotherapy versus intraperitoneal chemotherapy in recurrent ovarian cancer
Study: NCT05679947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization protocol
Description: The mobilization protocol includes six levels. Protocol levels are applied from the day the patient is operated and ends on the day of discharge. The researcher explains the protocol levels to the patient before surgery.The patient is mobilized within the first 24 hours after surgery. Implement mobilization protocol three times during the day and more as tolerated. Mobilization protocol:Level 1: Repositioning should occur every two hours. Level 2: Range of motion (PROM) should occur at least three times a day. Level 3: The head of bed (HOB) \>30 degrees. Duration goal: 5-15 minutes. HOB 65≥ degrees with patient sit in the bed. Duration goal: 5-15 minutes. Progress to level 4. Level 4: HOB 65≥ degrees with legs in dependent position (recliner chair). Duration goal: 5-15 minutes. Progress to level 5. Level 5: Stand/pivot/step to chair. Sitting in chair. Duration goal: 5-15 minutes. Progress to level 6. Level 6: Patient is able to ambulate at least three times a day.
Study: NCT04961385

Intervention type: BIOLOGICAL
Intervention: Immunogenicity after first dose of participants who received first dose of ChAdox-1 n COV-19 vaccine
Description: Blood samples were taken from the vaccinated participants for antibody testing against SARS-CoV-2
Study: NCT04932369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation training based on DBT
Description: trained about emotion regulation and problem solving during eight 90-min group sessions
Study: NCT05028790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single vision contact lens
Description: Participants will wear a single vision soft contact lens during the study visit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single vision contact lens
Description: Participants will wear a single vision soft contact lens during the study visit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal contact lens
Description: Participants will wear a multifocal soft contact lens during the study visit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal contact lens
Description: Participants will wear a multifocal soft contact lens during the study visit
Study: NCT05598424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Glucocorticoids
Description: Oral Glucocorticoids（methylprednisolone） 24mg qd, 2-week duration
Study: NCT05607693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680 tablets
Description: Subjects start taking SHR3680 tablets 240 mg/dose/day orally on an empty stomach on D1, and the timing of administration daily should be consistent when possible.
Study: NCT03224689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK-Optima Femoral Component
Description: TKA Surgery
Study: NCT05082259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: ASTX660 will be supplied as capsules. Each hydroxylpropyl methylcellulose (HPMC) capsule contains either 30 mg or 90 mg of ASTX600 free-base equivalents, suitable for oral administration. Bottles are labelled with the capsule strength (ie, 30 mg or 90 mg) and are further distinguished by different-colored labels. Each bottle contains 14 capsules and an oxygen-absorber (not to be consumed).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: ASTX660 will be supplied as capsules. Each hydroxylpropyl methylcellulose (HPMC) capsule contains either 30 mg or 90 mg of ASTX600 free-base equivalents, suitable for oral administration. Bottles are labelled with the capsule strength (ie, 30 mg or 90 mg) and are further distinguished by different-colored labels. Each bottle contains 14 capsules and an oxygen-absorber (not to be consumed).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier.~Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier.~Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material.
Study: NCT04726696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ROLE-AP programme
Description: The intervention group will be split in two groups of 7-8 primary care nurses each. These two groups will receive the ROLE-AP program over a three weeks period. Each workshop will be divided into two sessions of 90-120min. The first workshop focuses on the clarification of health promotion concepts and the discussion of the state of nursing practice in health promotion. Participants will discuss the misalignments between this description of nursing practice and the ideal one portrayed by the Ottawa Charter. The second workshop will allow the presentation of the objectives of the health care organization, showing its alignment with the Ottawa Charter areas of action. In addition, it will present a standardized instrument that reflects expectations about nurses' activities in health promotion that will serve for discussing and realigning participants' expectations on nurses' role in health promotion. The third workshop will continue with the discussion of nurses' expected activities.
Study: NCT04988555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-5336
Description: DSP-5336 orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-5336
Description: DSP-5336 orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-5336
Description: DSP-5336 orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-5336
Description: DSP-5336 orally
Study: NCT06048861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KForce Sens
Description: The device was attached to the middle of the wrist joint with the help of Velcro for all movements. Starting position of the extremity was determined and this position was introduced to the device as the reference position. Then, the participant was asked to perform the movement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KForce Sens
Description: The device was attached to the middle of the wrist joint with the help of Velcro for all movements. Starting position of the extremity was determined and this position was introduced to the device as the reference position. Then, the participant was asked to perform the movement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baseline Electrıgoniometer
Description: The pivot point of the goniometer was placed next to the ulnar styloid for 30° and 60° wrist flexion and extension, and also it was placed in the middle carpometacarpal joint for radial and ulnar deviation. A passive movement was made to the extremity in a predetermined amount and direction. The participant was asked to remember this position. Then, the participant was asked to return the extremity to this position when their eyes were closed.
Study: NCT06485050

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Application of red laser-photodynamic therapy using Rapid Podia Laser diode® (MEDENCY). The following protocol will be followed: 1) mechanical debridement of the nail, 2) disinfection of the nail with alcohol, 3) application of topical photosensitiser (Toluidine blue gel) for 5 minutes with the area covered, 5) application of 635 nm diode laser for 10 minutes.~Daily application of ciclopirox 8% with ethyl acetate, ethanol (96%), ketosteryl alcohol, hydroxypropyl chitosan and purified water.
Study: NCT05975619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyperSight imaging
Description: Subjects are scheduled for 1 to 5 HyperSight imaging sessions, which will occur on the same days as their standard clinical visits during planning and treatment delivery. A total of 5 to 10 HyperSight CBCT images will be acquired over all imaging sessions.
Study: NCT06174103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiVACOR TAH System
Description: The BiVACOR pump is an implantable rotary biventricular blood pump that uses magnetic levitation technology for increased durability to replace both ventricles of a failing heart. The device is intended to replace the diseased heart in patients suffering from heart failure to bridge the time to heart transplant.
Study: NCT05002257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Patients included in the intervention arm with music therapy will choose among 3 possible music: music from elsewhere, classical music, today's music. These 3 music thearpy will have an identical duration of 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No music therapy
Description: Usual care
Study: NCT04952805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD0004J08
Description: MAD0004J08 is a human monoclonal Antibody (mAb), 2.5 mL 2R vial available in two dose: 100 mg and 400 mg. The pharmaceutical form is solution for intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD0004J08
Description: MAD0004J08 is a human monoclonal Antibody (mAb), 2.5 mL 2R vial available in two dose: 100 mg and 400 mg. The pharmaceutical form is solution for intramuscular injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to MAD0004J08, 2.5 mL 2R vial. The pharmaceutical form is solution for intramuscular injection.
Study: NCT06378450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation guided practice
Description: Participants will listen to recordings of mindfulness meditation practices from a newly developed 28-day program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation guided practice
Description: Participants will listen to recordings of mindfulness meditation practices from a newly developed 28-day program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness meditation guided practice
Description: Participants will listen to recordings of mindfulness meditation practices from a newly developed 28-day program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation guided practice
Description: Participants will listen to recordings of mindfulness meditation practices from a newly developed 28-day program.
Study: NCT04734210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.02% Betamethasone Sodium Phosphate
Description: topical corticosteroid solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.04% Betamethasone Sodium Phosphate
Description: topical corticosteroid solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical vehicle solution
Study: NCT06634576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smooth pursuit neck torsion test
Description: Used custom-made system to stimulate the procedure of smooth pursuit neck torsion test in the current study, the multiple axis motion platform can adjust the neck postures to three different neck motion planes, seven different neck postures.
Study: NCT06634485

Intervention type: DEVICE
Intervention: ultrasound, spirometry
Description: Ultrasound assessment of~1. diaphragmatic excursion:-the probe will be angled medially ,cranially , and dorsally so that the ultrasound beam reaches the posterior third of the diaphragm, in B-mode.Then, then M-mode exploration line will be placed perpendicular to the diaphragmatic dome to obtain maximum excursion .~2. (Tdi) will be measured using a high-frequency linear probe (10 MHz) placed on (ZA).The probe will be angled perpendicular to the lateral chest wall and placed between the midaxillary and anterior axillary lines at the eighth or ninth intercostal space.~3. Quadricep\|rectus femoris muscle assessment will be done by placing the transducer perpendicular to the long axis of the thigh.~   * Spirometry:-will be performed thrice by experienced technicians at our pulmonary function laboratory. Patients will be asked to take a maximal inspiration and then to forcefully expel air for as long and as quickly as possible.

Intervention type: DEVICE
Intervention: ultrasound, spirometry
Description: Ultrasound assessment of~1. diaphragmatic excursion:-the probe will be angled medially ,cranially , and dorsally so that the ultrasound beam reaches the posterior third of the diaphragm, in B-mode.Then, then M-mode exploration line will be placed perpendicular to the diaphragmatic dome to obtain maximum excursion .~2. (Tdi) will be measured using a high-frequency linear probe (10 MHz) placed on (ZA).The probe will be angled perpendicular to the lateral chest wall and placed between the midaxillary and anterior axillary lines at the eighth or ninth intercostal space.~3. Quadricep\|rectus femoris muscle assessment will be done by placing the transducer perpendicular to the long axis of the thigh.~   * Spirometry:-will be performed thrice by experienced technicians at our pulmonary function laboratory. Patients will be asked to take a maximal inspiration and then to forcefully expel air for as long and as quickly as possible.
Study: NCT06634810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management Support
Description: The intervention will be delivered by CHWs in person and supplemented with telephone or video encounters over 6 months. The intervention comprises six core elements: engagement, intake, self-management assessment, barrier screening, actions to address identified barriers, and follow-up/maintenance support.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: COPD Education
Description: The attention control is where CHWs will provide COPD education using the COPD 1-2-3 booklet. The attention control will consist of 6 CHW visits (approximately 1 per month) with the patient and care giver in their home or via video conference, per patient preference.
Study: NCT06442462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPG302
Description: small synthetic molecule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06385938

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound with quantitative vibro-acoustic assessment
Description: Imaging with non-invasive bone assessment based on wide range of frequencies and free from soft tissue artifact of the wrists and the knees

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound with quantitative vibro-acoustic assessment
Description: Imaging with non-invasive bone assessment based on wide range of frequencies and free from soft tissue artifact of the wrists and the knees
Study: NCT06029270

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Given IV